ENHANCEMENT OF THERAPEUTIC EFFECTIVENESS OF METHOTREXATE AND PROTECTION OF NORMAL PROLIFERATING TISSUES WITH PURINES AND PYRIMIDINES

被引：42

作者：

HARRAP, KR ^{[1
]}

TAYLOR, GA ^{[1
]}

BROWMAN, GP ^{[1
]}

机构：

[1] INST CANC RES, DEPT BIOCHEM PHARMACOL, SUTTON, SURREY, ENGLAND

来源：

关键词：

D O I：

10.1016/0009-2797(77)90147-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：119 / 128

页数：10

共 20 条

[1] CHABNER BA, 1975, CANCER CHEMOTH REP 3, V6, P1
[2] DJERASSI I, 1975, CANCER CHEMOTH REP 3, V6, P3
[3] FREI E, 1975, NEW ENGL J MED, V292, P846
[4] METHOTREXATE TOXICITY - CORRELATION WITH DURATION OF ADMINISTRATION, PLASMA LEVELS, DOSE AND EXCRETION PATTERN
GOLDIE, JH
HARRAP, KR
PRICE, LA
[J]. EUROPEAN JOURNAL OF CANCER, 1972, 8 (04) : 409 - &
[5] ERADICATION OF LEUKAEMIC CELLS (L1210) BY METHOTREXATE AND METHOTREXATE PLUS CITROVORUM FACTOR
GOLDIN, A
VENDITTI, JM
KLINE, I
MANTEL, N
[J]. NATURE, 1966, 212 (5070) : 1548 - &
[6] GOLDIN A, 1954, CANCER RES, V14, P43
[7] HRYNIUK WM, 1975, CANCER RES, V35, P1427
[8] HRYNIUK WM, 1975, CANCER RES, V35, P1085
[9] JAFFE N, 1972, CANCER-AM CANCER SOC, V30, P1627, DOI 10.1002/1097-0142(197212)30:6<1627::AID-CNCR2820300631>3.0.CO
[10] 2-H